Fe(II)-induced DNA damage in α-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: Detection by the Comet assay

Journal of Neurochemistry

Volumn 87, Issue 3, 2003, Pages 620-630

  Martin, Francis L ^a   Williamson, Sally J M ^a   Paleologou, Katerina E ^a   Hewitt, Rebecca ^a   El Agnaf, Omar M A ^a   Allsop, David ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

synuclein; Comet assay; DNA SSBs; Fe(II); Neuroblastoma cells; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CYTARABINE; FERROUS ION; HYDROXYUREA; ROTENONE;

ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOPAMINERGIC NERVE CELL; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEWY BODY; MISSENSE MUTATION; MITOCHONDRIAL RESPIRATION; NEUROBLASTOMA CELL; PARKINSON DISEASE; PRIORITY JOURNAL;

ALPHA-SYNUCLEIN; AMINO ACID SUBSTITUTION; CELL LINE, TUMOR; COMET ASSAY; CYTARABINE; DNA; DNA DAMAGE; DNA REPAIR; DOPAMINE; ELECTRON TRANSPORT; FERROUS COMPOUNDS; HUMANS; HYDROXYUREA; NERVE TISSUE PROTEINS; NEUROBLASTOMA; ROTENONE; SYNUCLEINS; TRANSFECTION; UNCOUPLING AGENTS;

EID: 0142241356     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02013.x     Document Type: Article

References (42)

1. Abeliovich A., Schmitz Y., Farinas I. et al. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
2. Baba M., Nakajo S., Tu P. H., Tomita T., Nakaya K., Lee V. M., Trojanowski J. Q. and Iwatsubo T. (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884.
3. Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. and Lansbury P. T. Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571-576.
4. da Costa C. A., Ancolio K. and Checler F. (2000) Wild-type but not Parkinson's disease-related Ala-53 → Thr mutant α-synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem. 275, 24065-24069.
5. 53 to Thr on the physical and morphological properties of α-synuclein protein implicated in Parkinson's disease. FEBS Letts. 440, 67-70.
6. El-Agnaf O. M. A., Jakes R., Curran M. D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D. and Wallace A. (1998b) Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS Letts. 440, 71-75.
7. Feany M. B. and Bender W. W. (2000) A drosophila model of Parkinson's disease. Nature 404, 394-398.
8. Gabbita S. P., Lovell M. A. and Markesbery W. R. (1998) Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 71, 2034-2040.
9. George J. M., Jin H., Woods W. S. and Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-372.
10. Giovannelli L., Decorosi F., Dolara P. and P'ulvirenti L. (2003) Vulnerability to DNA damage in the aging rat substantia nigra: a study with the comet assay. Brain Res. 969, 244-247.
11. Hashimoto M., Hsu L. J., Rockenstein E., Takenouchi T., Mallory M. and Masliah E. (2002) α-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J. Biol. Chem. 277, 11465-11472.
12. Hsu L. J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M. and Masliah E. (2000) α-Synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410.
13. Kholodilov N. G., Neystat M., Oo T. F., Lo S. E., Larsen K. E., Sulzer D. and Burke R. E. (1999) Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J. Neurochem. 73, 2586-2599.
14. Kienzl E., Puchinger L., Jellinger K., Linert W., Stachelberger H. and Jameson R. F. (1995) The role of transition metals in the pathogenesis of Parkinson's disease. J. Neurol. Sci. Suppl. 134, 69-78.
15. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Gen. 18, 106-108.
16. Lee M., Hyun D., Halliwell B. and Jenner P. (2001) Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J. Neurochem. 76, 998-1009.
17. Li N., Ragheb K., Lawler G., Sturgis J., Rajwa B., Melendez J. A. and Robinson J. P. (2003) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 278, 8516-8525.
18. Lloyd D. R. and Phillips D. H. (1999) Oxidative DNA damage mediated -by copper (II), iron (II) and nickel (II) Fenton reactions: evidence for site-specific mechanisms in the formation of double-strand breaks, 8-hydroxydeoxyguanosine and putative intrastrand cross-links. Mutat. Res. 424, 23-36.
19. Lloyd D. R., Phillips D. H. and Carmichael P. L. (1997) Generation of putative intrastrand cross-links and strand breaks in DNA by transition metal ion-mediated oxygen radical attack. Chem. Res. Toxicol. 10, 393-400.
20. Martin F. L., Venitt S., Carmichael P. L., Crofton-Sleigh C., Stone E. M., Cole K. J., Gusterson B. A., Grover P. L. and Phillips D. H. (1997) DNA damage in breast epithelial cells: detection by the single-cell gel (comet) assay and induction by human mammary lipid extracts. Carcinogenesis 18, 2299-2305.
21. Martin F. L., Cole K. J., Orme M. H., Grover P. L., Phillips D. H. and Venitt S. (1999) The DNA repair inhibitors hydroxyurea and cytosine arabinoside enhance the sensitivity of the alkaline single-cell gel electrophoresis ('comet') assay in metabolically-competent MCL-5 cells. Mutat. Res. 445, 21-43.
22. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265-1269.
23. Migliore L., Petrozzi L., Lucetti C. et al. (2002) Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58, 1809-1815.
24. Mizuno Y., Hattori N. and Mori H. (1999) Genetics of Parkinson's disease. Biomed. Pharmacother 53, 109-116.
25. Obata T. (2002) Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping. Toxicol. Lett. 132, 83-93.
26. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J. M., Farer M. and Wolozin B. (2000) The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20, 6048-6054.
27. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
28. Seo J. H., Rah J. C., Choi S. H. et al. (2002) α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 16, 1826-1828.
29. Sharon R., Goldberg M. S., Bar-Josef I., Betensky R. A., Shen J. and Selkoe D. J. (2001) α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl Acad. Sci. USA 98, 9110-9115.
30. Sharon R., Bar-Joseph I., Frosch M. P., Walsh D. M., Hamilton J. A. and Selkoe D. J. (2003) The formation of highly soluble oligomers of α-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583-595.
31. Shastry B. S. (2001) Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci. Res. 41, 5-12.
32. Souza J. M., Giasson B. I., Lee V. M. and Ischiropoulos H. (2000) Chaperone-like activity of synucleins. FEBS Lett. 474, 116-119.
33. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. and Goedert M. (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469-6473.
34. Stefanis L., Kholodilov N., Rideout H. J., Burke R. E. and Greene L. A. (2001) Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. J. Neurochem, 76, 1165-1176.
35. Tabner B. J., Turnbull S., El-Agnaf O. M. A. and Allsop D. (2001) Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. Curr. Top. Med. Chem. 1, 507-517.
36. Tabner B. J., Turnbull S., El-Agnaf O. M. A. and Allsop D. (2002) Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic. Biol. Med. 32, 1076-1083.
37. Thompson K. J., Shoham S. and Connor J. R. (2001) Iron and neurodegenerative disorders. Brain Res. Bull. 55, 155-164.
38. Thong P. S. P., Watt F., Ponraj D., Leong S. K., He Y. and Lee T. K. Y. (1999) Iron and cell death in Parkinson's disease: a nuclear microscopic study into iron-rich granules in the parkinsonian substantia nigra of primate models. Nuclear Instr. Meth Physics Res. B 158, 349-355.
39. Turnbull S., Tabner B. J., El-Agnaf O. M. A., Moore S., Davies Y. and Allsop D. (2001) Alpha-synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med. 30, 1163-1170.
40. Van der Putten H., Wiederhold K. H., Probst A. et al. (2000) Neuropathology in mice expressing human α-synuclein. J. Neurosci. 20, 6021-6029.
41. Yared E., McMillan T. J. and Martin F. L. (2002) Genotoxic effects of oestrogens in breast cells detected by the micronucleus assay and the Comet assay. Mutagenesis 17, 345-352.
42. Zhang Y., Dawson V. L. and Dawson T. M. (2000) Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. 7, 240-250.